EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting neutrophil elastase is a promising direction for future cancer treatment

Wangqiang Jia, Yudong Mao, Qianwen Luo, Jiang Wu, Quanlin Guan

Discover Oncology · 15.05.2024 · 15 (1)

DOI: 10.1007/s12672-024-01010-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Discover Oncology, online erschienen am 15.05.2024. Verfasst von Wangqiang Jia und 4 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Lanzhou University, Lanzhou, China. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the major R&D Plan of Gansu Provincial Department of Science and Technology, the hospital fund project of the First Hospital of Lanzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neutrophil elastase (NE) is a proteolytic enzyme released extracellular during the formation of neutrophil extracellular traps (NETs) through degranulation. In addition to participating in the body's inflammatory response, NE also plays an important role in cancer. It can promote tumor proliferation, migration, and invasion, induce epithelial-mesenchymal transition (EMT), and change the tumor microenvironment (TME) to promote tumor progression. Concurrently, NE promotes systemic treatment resistance by inducing EMT. However, it can also selectively kill cancer cells and attenuate tumor development. Sivelestat is a specific NE inhibitor that can be used in the perioperative period of esophageal cancer patients to reduce the incidence of postoperative complications after esophagectomy. In addition, the combination of sivelestat and trastuzumab can enhance the efficacy of human epidermal growth factor receptor 2(HER 2) positive breast cancer patients. Meanwhile, targeting the human antibody domains and fragments of NE is also a new way to treat cancer and inflammation-related diseases. This review provides valuable insights into the role of NE in cancer treatment. Additionally, we discuss the challenges associated with the clinical application of sivelestat. By shedding light on the promising potential of NE, this review contributes to the advancement of cancer treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

CancerMetastasisNeutrophil elastaseProliferationSivelestat

Autor:innen und Institutionen

  • The First Clinical Medical College of Lanzhou University, Lanzhou, China.
  • The First Clinical Medical College of Lanzhou University, Lanzhou, China. guanql@lzu.edu.cn.
  • Department of Oncology Surgery, the First Hospital of Lanzhou University, No. 1, Donggang West Road, Lanzhou, 730000, Gansu Province, China. guanql@lzu.edu.cn.

Förderung

  • the major R&D Plan of Gansu Provincial Department of Science and Technology
  • the hospital fund project of the First Hospital of Lanzhou University

Zitieren

APA

Jia, W., Mao, Y., Luo, Q., Wu, J., & Guan, Q. (2024). Targeting neutrophil elastase is a promising direction for future cancer treatment. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01010-3

Vancouver

Jia W, Mao Y, Luo Q, Wu J, Guan Q. Targeting neutrophil elastase is a promising direction for future cancer treatment. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01010-3

BibTeX
@article{Jia2024,
  author = {Jia, Wangqiang and Mao, Yudong and Luo, Qianwen and Wu, Jiang and Guan, Quanlin},
  title = {Targeting neutrophil elastase is a promising direction for future cancer treatment},
  journal = {Discover Oncology},
  year = {2024},
  volume = {15},
  number = {1},
  doi = {10.1007/s12672-024-01010-3}
}
Kostenlos starten →